Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War Datamonitor, Dec 2004, Pages: 329   Description     Table of Contents        Enquire before Buying    Send to a Friend   Introduction According to the WHO, 350400 million are chronically infected with HBV and 170200 million with HCV. Although HBV vaccination and routine screening of donated blood has decreased incidence, the death toll resulting from chronic disease, cirrhosis and HCC is as high as one million per year (WHO, 2002). For HCV related conditions, this number will increase further over the next 1020 years. Scope Comprehensive overview of HBV and HCV epidemiology with comment on latest dynamics Analysis of drug treatment choice per line therapy per region for both HBV and HCV Discussion with key opinion leaders with regard to clinical and non-clinical attributes of therapy Future outlook for new HBV and HCV therapies along with unmet needs assessment Highlights While diagnosis rates of HBV has remained flat since 2002, HCV diagnosis rates have increased 2-4 fold with highest growth in Japan. Based on current estimates of prevalence, diagnosis and treatment current patient pools of between 1.8-2.0 million per disease. To increase the treatment pool, manufacturers of hepatitis treatments can either tap into a substantial amount of unidentified cases or meet the needs of non-responder or difficult to treat patients. Reasons to Purchase Gain up-to-date understanding of current therapy usage and selection choices per region Review current head-to-head competition between PEG-Intron and Pegasys per region Justify internal unmet needs assessment per disease versus external viewpoint Customers who bought this item also bought Strategic Perspectives: Hepatitis B and C - Strategic Developments in an Immature Market Commercial Perspectives: Hepatitis B and C - The Chinese Way? Treatment Algorithms 2002: Hepatitis B and C Commercial Insight: Hepatitis B and C - Awaiting New Developments Antiviral Drug Licensing Opportunities: Analysis, Rating, and Ranking - A Worldwide Study Pipeline Perspectives: Hepatitis B and C - Antivirals Challenge the Interferons? New Pegylated Interferons: Assessing the Impact of the New Longer Acting Interferons on the Hepatitis C Market Pipeline Perspectives: Hepatitis B and C - Antivirals Challenge the Interferons?

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster